31 results
DEFM14A
FUSN
Fusion Pharmaceuticals Inc
25 Apr 24
Proxy related to merger
4:13pm
, presentation or package configuration, that contains or comprises, including in combination with any other active ingredient(s), the product candidate
PREM14A
FUSN
Fusion Pharmaceuticals Inc
10 Apr 24
Preliminary proxy related to merger
4:42pm
product, in any dosage form, formulation, presentation or package configuration, that contains or comprises, including in combination with any other active
DEFA14A
FUSN
Fusion Pharmaceuticals Inc
19 Mar 24
Additional proxy soliciting materials
6:25am
.
“Product” means any product, in any dosage form, formulation, presentation or package configuration, that contains or comprises, including
8-K
EX-2.1
aex v070fmjvbs0vk
19 Mar 24
Voting and Support Agreement
6:24am
DEFA14A
kell26q
27 Apr 23
Additional proxy soliciting materials
4:34pm
DEF 14A
kn5bj43qjow9sl
27 Apr 21
Definitive proxy
4:02pm
10-K
n4tqv1mafu1 vxl8p
25 Mar 21
Annual report
8:01am
10-K
EX-10.24
dn9t7ww2h54siurd4u
25 Mar 21
Annual report
8:01am
8-K
EX-10.1
bglvljwhbr17c 4f1
2 Mar 21
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN-1087, a Small Molecule Targeting NTSR1, from Ipsen
9:00am
8-K
EX-10.1
sh5x61ofd yx5na
2 Nov 20
Entry into a Material Definitive Agreement
7:11am
424B4
hufzx louzuuyq64lnnb
26 Jun 20
Prospectus supplement with pricing info
4:47pm